サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451545

不眠症市場レポート：治療タイプ、薬剤クラス別、流通チャネル、地域別、2024-2032

Insomnia Market Report by Therapy Type, Drug Class, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 143 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
不眠症市場レポート：治療タイプ、薬剤クラス別、流通チャネル、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の不眠症市場規模は2023年に52億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて2.69%の成長率（CAGR）を示し、2032年までに市場は66億米ドルに達すると予測しています。

不眠症は、エネルギーレベルを低下させ、個人の気分、健康、仕事のパフォーマンス、全体的な生活の質に影響を与える睡眠障害です。その一般的な原因には、ストレス、長期の旅行、多忙な仕事のスケジュール、睡眠習慣の悪化、暴飲暴食、ニコチン、カフェイン、アルコールの過剰摂取などがあります。また、心的外傷後ストレスなどの精神疾患や、喘息や血圧のための抗うつ薬、鎮痛・アレルギー・風邪のための一般用医薬品（OTC）などの薬物の使用と関連することもあります。認知行動療法（CBT）、OTC睡眠補助薬、エスゾピクロンやラメルテオンのような処方薬など、その治療オプションは現在世界中で利用可能です。

不眠症の市場動向：

コロナウイルス感染症（COVID-19）の大流行は、社会的孤立や無数の仕事上の課題、家族の義務など、生活にかつてない変化をもたらしました。これは、数百万人の睡眠パターンに影響を与え、市場の成長を強化する大きなストレスとなる出来事でした。さらに、慢性疼痛、がん、糖尿病、心臓病、喘息、胃食道逆流症（GERD）、過活動甲状腺、パーキンソン病、アルツハイマー病などの病状は、通常不眠症と関連しています。したがって、これらの病気に苦しむ人の増加が、不眠症治療薬の需要を押し上げています。これとは別に、月経周期や更年期におけるホルモンの変化は、不眠症の発症リスクにつながる可能性があり、これが市場の成長に寄与しています。さらに、睡眠パターン、活動、健康の変化や処方薬の使用増加により、高齢者の不眠症の可能性が高まるため、世界の老人人口の増加が不眠症治療薬の需要を刺激しています。さらに、不眠症の予防、検出、治療、管理のための新しい治療法、介入、検査の試験への投資が増加しており、市場を牽引すると予想されています。

本レポートで扱う主な質問

  • 2023年の世界の不眠症市場規模は？
  • 2024年から2032年にかけての世界の不眠症市場の予想成長率は？
  • 世界の不眠症市場を牽引する主要因は何か？
  • COVID-19が世界の不眠症市場に与えた影響は？
  • 治療タイプ別世界の不眠症市場の内訳は？
  • 薬剤クラス別不眠症の世界市場の内訳は？
  • 不眠症の世界市場における主要地域は？
  • 不眠症の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の不眠症市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 非薬物療法
    • 市場動向
    • 主要セグメント
      • 催眠療法
      • 認知行動療法
      • 医療機器
      • その他
    • 市場予測
  • 薬物療法
    • 市場動向
    • 主要セグメント
      • 処方睡眠補助薬
      • 市販の睡眠補助薬
    • 市場予測

第7章 市場内訳：薬剤クラス別

  • 抗うつ薬
    • 市場動向
    • 市場予測
  • メラトニン拮抗薬
    • 市場動向
    • 市場予測
  • ベンゾジアゼピン
    • 市場動向
    • 市場予測
  • 非ベンゾジアゼピン系
    • 市場動向
    • 市場予測
  • オレキシン拮抗薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • ドラッグストア
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Astellas Pharma Inc.
    • Aurobindo Pharma Limited
    • Biocodex
    • Eisai Co. Ltd.
    • Mallinckrodt Pharmaceuticals
    • Merck & Co. Inc.
    • Neurim Pharmaceuticals Inc.
    • Pfizer Inc.
    • Sanofi S.A.
    • Sumitomo Dainippon Pharma Co. Ltd.（Sumitomo Chemical Co. Ltd.）
    • Takeda Pharmaceutical Company Limited
    • Vanda Pharmaceuticals Inc.
図表

List of Figures

  • Figure 1: Global: Insomnia Market: Major Drivers and Challenges
  • Figure 2: Global: Insomnia Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Insomnia Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Insomnia Market: Breakup by Therapy Type (in %), 2023
  • Figure 5: Global: Insomnia Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Insomnia Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Insomnia Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Insomnia (Non-Pharmacological Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Insomnia (Non-Pharmacological Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Insomnia (Pharmacological Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Insomnia (Pharmacological Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Insomnia (Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Insomnia (Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Insomnia (Melatonin Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Insomnia (Melatonin Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Insomnia (Benzodiazepines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Insomnia (Benzodiazepines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Insomnia (Nonbenzodiazepines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Insomnia (Nonbenzodiazepines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Insomnia (Orexin Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Insomnia (Orexin Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Insomnia (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Insomnia (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Insomnia (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Insomnia (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Insomnia (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Insomnia (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Insomnia (Drug Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Insomnia (Drug Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Insomnia (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Insomnia (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Insomnia Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Insomnia Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Insomnia Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Insomnia Industry: SWOT Analysis
  • Figure 82: Global: Insomnia Industry: Value Chain Analysis
  • Figure 83: Global: Insomnia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Insomnia Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Insomnia Market Forecast: Breakup by Therapy Type (in Million US$), 2024-2032
  • Table 3: Global: Insomnia Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Insomnia Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Insomnia Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Insomnia Market: Competitive Structure
  • Table 7: Global: Insomnia Market: Key Players
目次
Product Code: SR112024A6148

The global insomnia market size reached US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.6 Billion by 2032, exhibiting a growth rate (CAGR) of 2.69% during 2024-2032.

Insomnia is a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its common causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, and excessive consumption of nicotine, caffeine, and alcohol. It can also be associated with mental health disorders, such as post-traumatic stress, and the use of drugs like antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergy, and cold. Its treatment options, such as cognitive-behavioral therapy (CBT), OTC sleep aids, and prescription medications like Eszopiclone and Ramelteon, are currently available worldwide.

Insomnia Market Trends:

The coronavirus disease (COVID-19) pandemic generated unprecedented changes in lives, including social isolation and innumerable work challenges and family obligations. This acts as a major stressful event that impacted the sleep patterns of millions and strengthened the market growth. Moreover, medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson's disease, and Alzheimer's disease, are usually linked with insomnia. Hence, the increasing number of individuals suffering from these ailments is driving the demand for insomnia medications. Apart from this, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is contributing to the market growth. In addition, as changes in sleep patterns, activity, and health and the rising use of prescription drugs can increase the chance of insomnia among older people, the growing geriatric population globally is catalyzing the demand for insomnia medical treatment. Furthermore, increasing investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are anticipated to drive the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global insomnia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapy type, drug class and distribution channel.

Breakup by Therapy Type:

Non-Pharmacological Therapy

Hypnotherapy

Cognitive Behavioral Therapy

Medical Devices

Others

Pharmacological Therapy

Prescription Sleep Aids

Over-The-Counter Sleep Aids

Breakup by Drug Class:

Antidepressants

Melatonin Antagonist

Benzodiazepines

Nonbenzodiazepines

Orexin Antagonist

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global insomnia market in 2023?
  • 2. What is the expected growth rate of the global insomnia market during 2024-2032?
  • 3. What are the key factors driving the global insomnia market?
  • 4. What has been the impact of COVID-19 on the global insomnia market?
  • 5. What is the breakup of the global insomnia market based on the therapy type?
  • 6. What is the breakup of the global insomnia market based on the drug class?
  • 7. What are the key regions in the global insomnia market?
  • 8. Who are the key players/companies in the global insomnia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Insomnia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy Type

  • 6.1 Non-Pharmacological Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Hypnotherapy
      • 6.1.2.2 Cognitive Behavioral Therapy
      • 6.1.2.3 Medical Devices
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Pharmacological Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Prescription Sleep Aids
      • 6.2.2.2 Over-The-Counter Sleep Aids
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Antidepressants
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Melatonin Antagonist
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Benzodiazepines
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Nonbenzodiazepines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Orexin Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Drug Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Online Pharmacies
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Aurobindo Pharma Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Biocodex
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Mallinckrodt Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Neurim Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Vanda Pharmaceuticals Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials